{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:37:59Z","timestamp":1780090679353,"version":"3.54.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Obwohl das kutane Melanom nur etwa 4\u202f% aller Hautkrebsarten (einschlie\u00dflich des nichtmelanozyt\u00e4ren Hautkrebses) ausmacht, ist es f\u00fcr 80\u202f% aller durch Hautkrebs verursachten Todesf\u00e4lle verantwortlich. Die Einf\u00fchrung von Immuncheckpointinhibitoren f\u00fchrte zu einer erheblichen Verbesserung des Langzeit\u00fcberlebens von Patienten im fortgeschrittenen Stadium unabh\u00e4ngig vom <jats:italic>BRAF<\/jats:italic>-Mutations-Status. Neben der zielgerichteten Therapie f\u00fcr Patienten mit <jats:italic>BRAF<\/jats:italic>-mutiertem Melanom sind Immuntherapien die Behandlungsoptionen der Wahl im fortgeschrittenen Stadium und seit 2018 auch in der adjuvanten Therapie. Aktuell wird in Studien die Wirksamkeit von Therapiekombinationen sowie Sequenztherapien mit zielgerichteten und Immuntherapien gepr\u00fcft.<\/jats:p>","DOI":"10.1007\/s00108-020-00812-1","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T12:02:52Z","timestamp":1590580972000},"page":"669-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immuntherapie beim malignen Melanom","Immunotherapy for malignant melanoma"],"prefix":"10.1007","volume":"61","author":[{"given":"A.","family":"Zaremba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. G.","family":"Griewank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Roesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"812_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","volume":"9","author":"BC Bastian","year":"2014","unstructured":"Bastian\u00a0BC (2014) The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 9:239\u2013271","journal-title":"Annu Rev Pathol"},{"key":"812_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.14694\/EDBK_175265","volume":"37","author":"KM Komatsubara","year":"2017","unstructured":"Komatsubara\u00a0KM et\u00a0al (2017) Advances in the treatment of advanced extracutaneous melanomas and nonmelanoma skin cancers. Am Soc Clin Oncol Educ Book 37:641\u2013650","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"812_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf\u00a0D et\u00a0al (2018) Melanoma. Lancet 392:971\u2013984","journal-title":"Lancet"},{"key":"812_CR4","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/jdv.12236","volume":"28","author":"M Arnold","year":"2014","unstructured":"Arnold\u00a0M et\u00a0al (2014) Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. J\u00a0Eur Acad Dermatol Venereol 28:1170\u20131178","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"812_CR5","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/annonc\/mdr128","volume":"23","author":"LM Hollestein","year":"2011","unstructured":"Hollestein\u00a0LM et\u00a0al (2011) Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol 23:524\u2013530","journal-title":"Ann Oncol"},{"key":"812_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel\u00a0S et\u00a0al (2017) Survival of patients with advanced metastatic melanoma: the impact of novel therapies\u2014update 2017. Eur J Cancer 83:247\u2013257","journal-title":"Eur J Cancer"},{"key":"812_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert\u00a0C et al (2019) Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N\u00a0Engl J Med 381:626\u2013636","journal-title":"N Engl J Med"},{"key":"812_CR8","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","volume":"29","author":"N Wagle","year":"2011","unstructured":"Wagle\u00a0N et\u00a0al (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J\u00a0Clin Oncol 29:3085\u20133096","journal-title":"J Clin Oncol"},{"key":"812_CR9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov\u00a0LB et\u00a0al (2013) Signatures of mutational processes in human cancer. Nature 500:415\u2013421","journal-title":"Nature"},{"key":"812_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis\u00a0E et\u00a0al (2012) A landscape of driver mutations in melanoma. Cell 150:251\u2013263","journal-title":"Cell"},{"key":"812_CR11","first-page":"OF11","volume":"7","author":"E Dolgin","year":"2017","unstructured":"Dolgin\u00a0E (2017) Immunotherapy combo offers slight survival benefit in melanoma. Cancer Discov 7:OF11","journal-title":"Cancer Discov"},{"key":"812_CR12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz\u00a0A et al (2017) Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 19:1189\u20131201","journal-title":"Cell Rep"},{"key":"812_CR13","doi-asserted-by":"publisher","first-page":"e0176822","DOI":"10.1371\/journal.pone.0176822","volume":"12","author":"T Zhao","year":"2017","unstructured":"Zhao\u00a0T, Li\u00a0C, Wu\u00a0Y, Li\u00a0B, Zhang\u00a0B (2017) Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: a meta-analysis. PLoS One 12:e176822","journal-title":"PLoS One"},{"key":"812_CR14","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert\u00a0C et al (2019) Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5\u2011year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 20:1239\u20131251","journal-title":"Lancet Oncol"},{"key":"812_CR15","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin\u00a0J et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N\u00a0Engl J Med 381:1535\u20131546","journal-title":"N Engl J Med"},{"key":"812_CR16","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","volume":"35","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf\u00a0D et\u00a0al (2017) Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J\u00a0Clin Oncol 35:3807\u20133814","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"812_CR17","first-page":"1310O","volume":"30","author":"JS Weber","year":"2019","unstructured":"Weber\u00a0JS et al (2019) Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III\/IV melanoma: 3\u2011year efficacy and biomarker results from the phase III CheckMate 238 trial. Ann Oncol 30(Suppl 5):1310O","journal-title":"Ann Oncol"},{"key":"812_CR18","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber\u00a0J et\u00a0al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N\u00a0Engl J Med 377:1824\u20131835","journal-title":"N Engl J Med"},{"key":"812_CR19","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont\u00a0AMM et\u00a0al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N\u00a0Engl J Med 378:1789\u20131801","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"812_CR20","first-page":"LBA67","volume":"30","author":"D Schadendorf","year":"2019","unstructured":"Schadendorf\u00a0D et al (2019) Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): a randomized, double-blind phase II trial (IMMUNED). Ann Oncol 30(Suppl 5):LBA67","journal-title":"Ann Oncol"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-020-00812-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-020-00812-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-020-00812-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T23:13:33Z","timestamp":1622070813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-020-00812-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1007\/s00108-020-00812-1","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"27 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Zaremba: A.\u00a0Finanzielle Interessen: Reisekostenunterst\u00fctzung von Novartis und Bristol-Myers Squibb. \u2013 B.\u00a0Nichtfinanzielle Interessen: Wissenschaftliche Angestellte, Klinik f\u00fcr Dermatologie, Venerologie und Allergologie, Universit\u00e4tsklinikum Essen. L.\u00a0Zimmer: A.\u00a0Finanzielle Interessen: Honorar: Bristol-Myers Squibb (BMS), Pierre Fabre, Merck Sharp & Dohme (MSD), Novartis | Reise\u2011\/\u00dcbernachtungskosten: Amgen, Sanofi, Pierre Fabre, BMS. \u2013 Advisory Boards: BMS, MSD, Roche, Pierre Fabre, Sanofi, Novartis. \u2013 B.\u00a0Nichtfinanzielle Interessen: Ober\u00e4rztin Hauttumorzentrum, Universit\u00e4tsklinikum Essen | Mitgliedschaften: Arbeitsgemeinschaft Dermatologische Onkologie, Deutsche Krebsgesellschaft, Deutsche Dermatologische Gesellschaft. K.G.\u00a0Griewank gibt an, dass kein Interessenkonflikt besteht. S.\u00a0Ugurel: A.\u00a0Finanzielle Interessen: Forschungsunterst\u00fctzung: Bristol-Myers Squibb und Merck Serono. \u2013 Reisekostenunterst\u00fctzung: Bristol-Myers Squibb, Merck Sharp & Dohme. \u2013 Bezahlte Beraterin\/interne Schulungsreferentin\/Gehaltsempf\u00e4ngerin oder \u00c4hnliches: Bristol-Myers Squibb, Merck Sharp & Dohme, Merck Serono, Novartis, Roche. \u2013 B.\u00a0Nichtfinanzielle Interessen: Ober\u00e4rztin an Universit\u00e4tsklinik | Vorstandsmitglied Arbeitsgemeinschaft Dermatologische Onkologie der Deutschen Krebsgesellschaft. A.\u00a0Roesch: A.\u00a0Finanzielle Interessen: Forschungsunterst\u00fctzung: Novartis, Bristol-Myers Squibb. \u2013 Bezahlte Beraterin\/interne Schulungsreferentin\/Gehaltsempf\u00e4ngerin oder \u00c4hnliches: Novartis, Bristol-Myers Squibb, Roche, MSD Sharp & Dohme \u2013 B.\u00a0Nichtfinanzielle Interessen: Wissenschaftlicher Mitarbeiter, Dermatologe (leitender Oberarzt), Klinik f\u00fcr Dermatologie, Universit\u00e4tsmedizin Essen, Essen. Mitgliedschaften: Deutsche Krebsgesellschaft\/Arbeitsgemeinschaft Dermatologische Onkologie, Deutsche Dermatologische Gesellschaft, Society for Melanoma Research. E.\u00a0Livingstone: A.\u00a0Finanzielle Interessen: Referentenhonorar oder Kostenerstattung als passive Teilnehmerin: Beraterhonorare und\/oder Referentenhonorare: Amgen, Actelion, Roche, BMS, MSD, Novartis, Janssen, Medac | Reisekostenzuschuss oder -erstattung: Amgen, MSD, BMS, Pierre Fabre, Sun Pharma und Novartis. \u2013 B.\u00a0Nichtfinanzielle Interessen: Wissenschaftliche Mitarbeiterin, Dermatologin (Ober\u00e4rztin), Klinik f\u00fcr Dermatologie, Universit\u00e4tsmedizin Essen, Essen | Mitgliedschaften: Arbeitsgemeinschaft Dermatologische Onkologie, Deutsche Dermatologische Gesellschaft, \u00c4rztinnenbund. D.\u00a0Schadendorf: A.\u00a0Finanzielle Interessen: Berater\u2011\/Referentenhonorar, Reise\u2011\/\u00dcbernachtungskosten: Roche, Novartis, BMS, MSD\/Merck, Merck-EMD, Amgen, Pierre Fabre, Pfizer, 4SC, Philogen, LEO Pharma, Regeneron\/Sanofi, AstraZeneca, Boehringer Ingelheim, MOLOGEN, InflaRX, NeraCare | Berater\u2011\/Referentenhonorar: Incyte, Array Biopharma | Beraterhonorar: Immunocore. \u2013 B.\u00a0Nichtfinanzielle Interessen: Universit\u00e4tsklinikum Essen, Direktor der Klinik f\u00fcr Dermatologie und Direktor des Westdeutschen Tumorzentrums, Essen. Mitgliedschaften: Deutsche Dermatologische Gesellschaft, American Society of Cancer Research (ASCR), Society for Investigative Dermatology (SID), European Organization for Research and Treatment of Cancer (EORTC) \u2013 Melanoma Cooperative Group, Deutsche Krebsgesellschaft, Arbeitsgemeinschaft Dermatologische Onkologie \u2013 Mitglied seit 1996, Pr\u00e4sident 2002\u20132018, American Society of Clinical Oncology (ASCO), Mitglied im Editorial Board des <i>European Journal of Cancer<\/i> (EJC), Gr\u00fcndungsmitglied der European Society for Cancer Immunology and Immunotherapy (ESCII), Association for Cancer Immunotherapy (CIMT).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}